The authors constructed a nomogram including age, Karnofsky Performance Status (KPS), extent of resection, MGMT promoter methylation status, chemoradiotherapy, and SII-NLR score to predict 2-year survival in patients with glioblastoma (the c-index of the nomogram was 0.848 (95% CI 0.836–0.861) and 0.843 (95% CI 0.830–0.855) excluding MGMT promoter methylation status) (129). This evidence concerns the gene MGMT and glioblastoma.